Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $51.1 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 124.14% year-over-year to $51.1 million; the TTM figure through Dec 2025 stood at $51.1 million (up 124.14% YoY), while the FY2025 annual figure was $51.1 million, up 124.14% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $51.1 million, down from $56.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $329.7 million in Q1 2024, with the low at $10.1 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $53.0 million (2022), against an average of $92.8 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 1320.49% in 2024, then slumped 96.93% in 2025.
• Dianthus Therapeutics' Cash & Equivalents stood at $131.6 million in 2021, then slumped by 88.33% to $15.4 million in 2022, then surged by 761.21% to $132.3 million in 2023, then sank by 82.78% to $22.8 million in 2024, then soared by 124.14% to $51.1 million in 2025.
• Business Quant data shows DNTH's Cash & Equivalents at $51.1 million in Q4 2025, $56.0 million in Q3 2025, and $13.2 million in Q2 2025.